drugset / Trial / NCT05041790
A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment
Phase 4
Unknown
418 enrolled
Chong Kun Dang Pharmaceutical
Choline Alfoscerate Re-evaluation Consortium (57 pharmaceutical companies) · collab
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a multi-center, randomized, double-blind, placebo-controlled, Phase IV trial to evaluate the efficacy and safety of Choline Alfoscerate compared to placebo in patients with degenerative mild cognitive impairment.
Timeline
- Start
- 2021-09-30
- Primary completion
- 2024-11-30
- Completion
- 2024-11-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Choline Alfoscerate | Unknown | 400 mg | Oral |